Digital health platforms expand access and improve care for male androgenetic alopecia.

Peter C Young¹, Chetan Mahajan², Jerry Shapiro³, Antonella Tosti⁴

¹Keeps Medical Group, New York, NY, USA.

²Thirty Madison, New York, NY, USA.

³The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, NY, USA.

⁴Department of Dermatology and Cutaneous Surgery, University of Miami, Miami, FL, USA.

PubMed PMC DOI PDF

Abstract

INTRODUCTION: Digital health solutions, specifically direct-to-consumer platforms, have been touted to make care accessible and convenient for patients. The aim of this article is to evaluate patients' reported reasons for choosing a platform for the treatment of hair loss and their experience. This platform (Keeps) is focused exclusively on the treatment of male pattern hair loss (MPHL) with appr…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.